ReviewJournal of Cancer2017

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Liting Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.